Abstract

Primary cutaneous mucinous carcinoma (PCMC) is rare, and its carcinogenesis is unclear. Trimethylation of histone H3 at lysine 27 (H3K27me3) is a key regulator in chromatin remodeling-controlled transcription. Focusing on the epigenetic mechanism, we aimed to investigate the expression of H3K27me3 in PCMC by immunohistochemistry. A retrospective cohort of PCMC patients from a tertiary hospital in Taiwan was enrolled to evaluate the clinicopathologic features, treatment outcome, and protein expression. Immunohistochemistry for H3K27me3 was performed on all PCMCs and a comparison group of colonic mucinous adenocarcinoma and pure mucinous carcinoma of the breast. The percentage of H3K27me3-negative tumor cells was calculated and analyzed. Three patients with PCMC were recruited. All PCMCs were solitary and slow growing, arising from the head-and-neck region. All PCMCs had tumor excision without local recurrence or metastasis. The loss of H3K27me3 expression was significant in PCMCs (mean ± standard deviation [SD]: 21.0% ± 6.6%) compared to other mucinous carcinomas (mean ± SD: 3.8% ± 1.7%) (P = 0.019). In conclusion, we report a reduction in H3K27me3 expression in PCMC. In contrast, H3K27me3 expression is retained or mildly reduced in other mucinous carcinomas. This is the first study to indicate a possible role of epigenetic events in the pathobiology of PCMC.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.